WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced its launch of the AsthmaMDTM Peak Flow Meter designed to help asthma patients to track and measure lung performance.
Asthma is a chronic disease characterized by recurrent attacks of breathlessness and wheezing which can vary in severity and frequency from person to person.1 According to the Centers for Disease Control, 1 in 13 people have asthma2 and each year, asthma causes 1.6 million emergency visits3 and 439,000 hospital stays.4
The AsthmaMDTM Peak Flow Meter was developed for use with the AsthmaMDTM smartphone app, which helps patients digitally log peak flow meter readings, track symptoms, medications, and notes – empowering patients to create a digital journal of their asthma activity. Offered currently as a complimentary download by AsthmaMD, Inc., * the smartphone companion app encourages patients to share their activity with their physician care team via the cloud-based MyAsthmaMDTM Physician Portal (also offered by AsthmaMD, Inc.).
“Teleflex is committed to connecting clinicians and patients with technology that improves patient outcomes,” said James Ferguson, President Respiratory Division, Teleflex Incorporated. “Asthma is the third-leading cause of hospitalization in children5 and Teleflex is proud to now offer the AsthmaMDTM Peak Flow Meter to help these and other asthma patients.”
To learn more about the asthma management portfolio from Teleflex, please visit Teleflex.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose-driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine, and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
*DISCLAIMER: The AsthmaMDTM mobile app and MyAsthmaMDTM Physician Portal are third-party products offered by AsthmaMD, Inc. Teleflex has no control over such third-party products, nor does Teleflex review, approve, monitor, endorse, or make any representations or warranties with respect to such third-party products.
Asthma. World Health Organization. http://www.who.int/topics/asthma/en/. Accessed March 22, 2017
Asthma. Centers for Disease Control. https://www.cdc.gov/asthma/default.htm. Accessed March 22, 2017
National Center for Health Statistics. Centers for Disease Control. https://www.cdc.gov/nchs/fastats/asthma.htm Accessed March 22, 2017
Most Recent Asthma Data. Centers for Disease Control. https://www.cdc.gov/asthma/most_recent_data.htm Accessed March 22, 2017
Asthma Facts. United States Environmental Protection Agency. https://www.epa.gov/sites/production/files/2016-05/documents/asthma_fact_sheet_english_05_2016.pdf Accessed March 22, 2017
AsthmaMD and MyAsthmaMD is a trademark of Genia Medical, Inc.
Teleflex, the Teleflex logo, and Hudson RCI are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2017 Teleflex Incorporated. All rights reserved. MC-003204